Benefits of Pola-R-CHP over other novel agents against newly diagnosed DLBCLApril 17, 2023B Cell Lymphoma
Addition of bortezomib to R-CHOP improves survival in DLBCL molecular subgroupsApril 17, 2023B Cell Lymphoma
Ibrutinib offers better efficacy and tolerability over idelalisib+rituximab in relapsed/refractory CLLApril 17, 2023B Cell Lymphoma
Dose-adjusted EPOCH and rituximab beneficial for selected older patients with high-risk DLBCLApril 17, 2023B Cell Lymphoma
Axi-cel a promising second-line treatment option for older patients with relapsed or refractory LBCLApril 17, 2023B Cell Lymphoma
Lenalidomide+rituximab+venetoclax a potential therapy option for untreated MCLApril 17, 2023B Cell Lymphoma
Higher rates of hospitalization, blood disorders, and infections among patients with MCLApril 17, 2023B Cell Lymphoma
Ibrutinib+BR a promising treatment option for newly diagnosed MCL ineligible for intensive therapyApril 17, 2023B Cell Lymphoma
Real-world data support the continued use of second-line targeted therapies in CLLApril 17, 2023B Cell Lymphoma
Commentary: Updates on the Treatment of Mantle Cell Lymphoma, April 2023 March 30, 2023B Cell Lymphoma
Standard first‐line chemotherapies for indolent B‐cell lymphoma impose varying risks for a second cancerMarch 23, 2023B Cell Lymphoma
High-dose total body irradiation followed by stem cell transplantation offers long-term survival in MCLMarch 23, 2023B Cell Lymphoma
A complete assessment of TP53 aberrations recommended before initiating ibrutinib in CLLMarch 23, 2023B Cell Lymphoma
